Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ruslan Korets

Urology Boston, MA Medical Doctor

NPI 1437316502 CMS profile 247069

330 Brookline Ave, Boston, MA 02215

Open in the dashboard

General payments

$86,205

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ruslan Korets of Boston, MA is reported in the CMS Open Payments database as having received $86,205 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,666 7
2024 General $13,478 15
2023 General $12,362 14
2022 General $18,243 20
2021 General $30,979 13
2020 General $3,444 2
2019 General $1,033 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ruslan Korets
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Ruslan Korets were reported at $6,666. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Ruslan Korets Urology median Middle half National median
2019 $1,033 $480 $147–$1,201 $163
2020 $3,444 $246 $87–$645 $114
2021 $30,979 $358 $111–$1,000 $132
2022 $18,243 $476 $143–$1,263 $149
2023 $12,362 $560 $168–$1,461 $160
2024 $13,478 $563 $170–$1,464 $164
2025 $6,666 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $70,495 63 payments
  2. Gyrus ACMI, Inc. $6,122 4 payments
  3. Intuitive Surgical, Inc. $3,593 6 payments
  4. Ambu A/S $3,265 2 payments
  5. Olympus Medical Systems Corporation $1,620 1 payment
  6. Olympus Winter & Ibe GmbH $1,080 1 payment
  7. Ambu Inc. $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $79,363 41 payments
  2. Education $3,000 1 payment
  3. Travel and Lodging $1,909 21 payments
  4. Honoraria $1,225 1 payment
  5. Food and Beverage $708 14 payments
Products named General payments · program years 2019–2025
  1. GENERAL KIDNEY STONE DISEASE $27,517 16 payments
  2. General - Kidney Stone Disease General - Kidney Stone Disease_URO $11,878 12 payments
  3. DAKOTA $4,800 1 payment
  4. URETERO-RENO FIBERSCOPE $3,578 2 payments
  5. General - Kidney Stone Disease Kidney Stone Disease $3,400 1 payment
  6. Moses 550 D\F\L $3,031 3 payments
  7. DA VINCI SP $3,000 1 payment
  8. Soltive $2,500 1 payment
  9. LithoVue $1,945 6 payments
  10. OES CHOLEDOCHOFIBERSCOPE $1,620 1 payment
  11. Other $3,454 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

243

Median for Urology: 1,053

Drug cost

$20,992

Median for Urology: $101,464

Branded share of claims

35%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 21 $17,109
Tamsulosin Hcl Generic 84 $1,362
Oxybutynin Chloride Er Oxybutynin Chloride Brand 18 $803
Cefpodoxime Proxetil Generic 27 $675
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 46 $522
Finasteride Generic 36 $472
Ciprofloxacin Hcl Generic 11 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$126,487

Medicare's payments for the services billed

Medicare patients

383

Average age 74

Services billed

952

66 women, 317 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Chronic kidney disease 33%
Diabetes 30%
Ischemic heart disease 28%
Cancer 25%
Depression 23%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record